Early research (Phase 1)Study completedNCT04144348
What this trial is testing
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Who this might be right for
Human Metapneumovirus and Human Parainfluenza Infection
ModernaTX, Inc. 51